Schering Aktiengesellschaft

Mitsui Chemicals, Inc.

Bayer Schering Pharma Ag

Eishi Tanaka

Tsuneji Suzuki

Tomoyuki Ando

Katsutoshi Tsuchiya

Yoshinori Shiraishi

Osamu Nakanishi

Akiko Saito

Takashi Yamashita

Hideki Kobayashi

Shinichi Banba

Nobuhiro Hirayama

Toshihiro Oikawa

Kiyoshi Ito

Toshifumi Yamaki

Kaori Matoishi

Katsuru Matsumoto

Junko Tobita

Tsuchiya Katsutoshi

A method of treating a malignant tumor selected from the group consisting of leukemia, colorectal cancer, ovarian cancer, oral cancer, lung carcinoma, breast carcinoma, prostate carcinoma, and melanoma by administering to a patient in need thereof an effective amount of at least one compound represented by formula (1) wherein A, X, Q, R, and n are defined herein.

Cell differentiation inducer

The novel benzamide derivative represented by formula (1) and the novel anilide derivative represented by formula (13) of this invention has differentiation-inducing effect, and are, therefore, useful a therapeutic or improving agent for malignant tumors, autoimmune diseases, dermatologic diseases and parasitism. In particular, they are highly effective as an anticancer drug, specifically to a hematologic malignancy and a solid carcinoma. 

The amino acid sequence of a mutant which is obtained by introducing a novel mutation into aJCM3095-derived nitrile hydratase consisting of two types of heterogeneous subunits, and the base sequence of the gene are provided. The nitrile hydratase is modified by specifying the region to be modified in the stereostructure/amino acid sequence of the nitrile hydratase, and applying alteration such as substitution, insertion, deletion or the like, to the amino acids in the amino acid sequence which are corresponding to the amino acid residues forming the region. Also provided is a method for modifying an enzyme having a nitrile hydratase activity.

Nitrile hydratase variant

The novel benzamide derivative represented by formula (1) and the novel anilide derivative represented by formula (13) of this invention has differentiation-inducing effect, and are, therefore, useful a therapeutic or improving agent for malignant tumors, autoimmune diseases, dermatologic diseases and parasitism. In particular, they are highly effective as an anticancer drug, specifically to a hematologic malignancy and a solid carcinoma.

Cell differentiation inducer, benzamide compounds

Benzamide derivatives and pharmaceutical compositions containing same

A resin composition is provided for an electro-photographic toner. The composition comprises 5 to 95 parts by weight of a high molecular weight vinyl copolymer polymer and 95 to 5 parts by weight of a low molecular weight vinyl copolymer. The former ethylene polymer has a weight average molecular weight (Mw) of from 200,000 to 1,000,000 and a ratio (Mw/Mn) of the weight average molecular weight (Mw) to a number average molecular weight (Mn) of from 8 to 300, and the latter vinyl copolymer has a weight average molecular weight of from 3,000 to 20,000. At least one of the former and latter vinyl copolymer, preferably, the former vinyl copolymer is an ethylene polymer which has been obtained by conducting polymerization in the presence of a monomer having an ionization potential of from 10.0 to 15.0 eV and a difference of from 9.0 to 15.0 eV in level between a highest occupied molecular orbital (HOMO) and a lowest unoccupied molecular orbital (LUMO), both determined by computational chemistry. The resin composition shows excellent charging characteristics even without a charge control agent or with a charge control agent in a reduced amount. A toner containing the resin composition is also provided.

Resin composition for electrophotographic toner, and toner

Growing community of inventors

Mobara, Japan

Eishi Tanaka